1.上海中医药大学附属曙光医院(上海 201203)
章诚杰,男,硕士,副主任医师,主要从事中医内科临床研究工作
蒋健,主任医师,博士研究生导师; E-mail:jiangjiansg@126.com
扫 描 看 全 文
章诚杰,姚轶立,周丹,等.干姜小柴胡汤治疗新型冠状病毒奥密克戎变异株感染轻型患者的临床观察[J].上海中医药杂志,2022,56(9):1-4.
ZHANG Chengjie,YAO Yili,ZHOU Dan,et al.Clinical observation on Ganjiang Xiaochaihu Decoction in treating patients with mild infection of COVID⁃19 Omicron variant[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(9):1-4.
章诚杰,姚轶立,周丹,等.干姜小柴胡汤治疗新型冠状病毒奥密克戎变异株感染轻型患者的临床观察[J].上海中医药杂志,2022,56(9):1-4. DOI: 10.16305/j.1007-1334.2022.2206067.
ZHANG Chengjie,YAO Yili,ZHOU Dan,et al.Clinical observation on Ganjiang Xiaochaihu Decoction in treating patients with mild infection of COVID⁃19 Omicron variant[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(9):1-4. DOI: 10.16305/j.1007-1334.2022.2206067.
目的,2,观察干姜小柴胡汤治疗新型冠状病毒奥密克戎变异株感染轻型患者的临床疗效。,方法,2,将145例新型冠状病毒奥密克戎变异株感染轻型患者随机分为治疗组(97例)和对照组(48例),对照组予基础治疗,治疗组在对照组治疗基础上加用干姜小柴胡汤。治疗5 d后观察临床疗效,比较两组中医证候积分、抑郁自评量表(SDS)评分、焦虑自评量表(SAS)评分及核酸转阴时间。,结果,2,①试验过程中,对照组脱落1例,最终完成试验者治疗组97例、对照组47例。②治疗组总有效率为99.0%,对照组总有效率为78.7%,治疗组临床疗效优于对照组(,P,<,0.05)。③治疗5 d后与治疗前组内比较,两组中医证候各分项积分及总积分均减少,差异有统计学意义(,P,<,0.05);组间治疗5 d后比较,治疗组咽部不适、鼻塞流涕、食欲不振、心情烦躁、心悸积分及中医证候总积分少于对照组,差异有统计学意义(,P,<,0.05)。④治疗5 d后与治疗前组内比较,两组SDS、SAS评分降低,差异有统计学意义(,P,<,0.05);组间治疗5 d后比较,治疗组SDS、SAS评分低于对照组,差异有统计学意义(,P,<,0.05)。⑤两组核酸转阴时间比较,差异无统计学意义(,P,>,0.05)。,结论,2,干姜小柴胡汤治疗新型冠状病毒奥密克戎变异株感染轻型患者疗效满意,可有效改善患者的中医证候,缓解抑郁、焦虑情绪,具有“病郁同治”的功效。
Objective,2,To observe the clinical effect of Ganjiang Xiaochaihu Decoction on patients with mild infection of COVID-19 Omicron variant.,Methods,2,One hundred and forty-five patients with mild infection of COVID-19 Omicron variant were randomly divided into a treatment group (,n,=97) and a control group (,n,=48). The control group was given basic routine treatment, while the treatment group was administered with Ganjiang Xiaochaihu Decoction and the basic routine treatment. After 5 days of treatment, the clinical effect was observed, and TCM syndrome scores, self-rating depression scale (SDS) scores, self-rating anxiety scale (SAS) scores and nucleic acid conversion time (NCT) were compared between the two groups.,Results,2,①During the trial, 1 case in the control group dropped out, and finally 97 cases in the treatment group and 47 cases in the control group completed the trial. ②The total effective rate of the treatment group was 99.0%, and that of the control group was 78.7%. The treatment group showed a better clinical effect compared with the control group (,P,<,0.05). ③After 5 days of treatment, the TCM syndrome sub-item scores and total scores in both groups decreased, and the differences were statistically significant (,P,<,0.05); After 5 days of treatment, the sub-item scores of pharyngeal discomfort, nasal obstruction and runny nose, loss of appetite, irritability, palpitation and the TCM syndrome total scores in the treatment group were lower than those in the control group, and the differences were statistically significant (,P,<,0.05). ④The scores of SDS and SAS in the two groups decreased after 5 days of treatment compared with those before treatment, and the differences were statistically significant (,P,<,0.05); After 5 days of treatment, the scores of SDS and SAS in the treatment group were lower than those in the control group, and the differences were statistically significant (,P,<,0.05). ⑤There was no statistically significant difference between the two groups in terms of nucleic acid conversion time (,P,>,0.05).,Conclusion,2,Ganjiang Xiaochaihu Decoction has achieved a satisfactory result in treating patients with mild infection of COVID-19 Omicron variant because it can effectively improve the patients’ TCM syndromes, relieve depression and anxiety, and has the effect of “simultaneous treatment of infection and depression”.
新型冠状病毒肺炎新型冠状病毒奥密克戎变异株小柴胡汤经典名方焦虑抑郁临床试验
COVID-19SARS-CoV-2Omicron variantXiaochaihu Decoctionclassical representative famous prescriptionanxietydepressionclinical trial
ZHANG X X, ZHANG W H, CHEN S J. Shanghai’s lifesaving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399(10340): 2011-2012.
张亮,吕莹,江珊,等. 三级综合性医院转为新型冠状病毒肺炎定点医院的医院感染防控WSR方法实践探索[J]. 上海中医药杂志,2022, 56(8): 7-11 .
国家卫生健康委员会办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL](2022-03-14)[2022-06-11]. http: //www.gov.cn/zhengce/ zhengceku/2022-03/15/5679257/files/49854a49c7004f 4ea9e622f3f2c568d8.pdfhttp://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf.
国家药品监督管理局. 中药新药临床研究指导原则(试行)[M]. 北京:中国医药科技出版社,2002.
王汝展,刘兰芬,崔开艳,等. ZUNG氏抑郁自评量表作为内科住院患者抑郁障碍筛查工具的可行性研究[J]. 中国健康心理学杂志,2009, 17(8): 923-925.
王文菁,许明智. 焦虑自评量表在精神疾病患者中的因子结构研究[J]. 广东医学,2009, 30(10): 1416-1418.
田琳,王檀,王子元,等. 2108例新型冠状病毒奥密克戎变异株感染患者的中医证候特征及诊疗策略探析[J]. 中华中医药学刊,2022, 40(5): 17-20.
陈博武,杨梦琪,温宗麟,等. 上海地区新型冠状病毒奥密克戎变异株感染轻症患者中医证候特征研究[J/OL]. 中医杂志,2022:1-5(2022-05-13)[2022-06-11]. http://kns.cnki.net /kcms/detail/11.2166.r.20220528.2018.002. htmlhttp://kns.cnki.net/kcms/detail/11.2166.r.20220528.2018.002.html.
于鲁璐,许银珠,李卫晖,等. 新冠肺炎疫情期间医务人员与非医务人员焦虑抑郁水平及相关因素[J]. 中国心理卫生杂志,2022, 36(5): 451-456.
上海市老年新型冠状病毒感染中医药救治工作专家共识撰写组. 上海市老年新型冠状病毒感染中医药救治工作专家共识[J]. 上海中医药杂志,2022, 56(6): 1-2.
蒋健. 郁证发微(一)——郁证形态论[J]. 上海中医药杂志,2015, 49(8): 4-7.
蒋健. 郁证发微(四十三)——郁证《伤寒杂病论》论[J]. 中医药临床杂志,2020, 32(1): 7-12.
蒋健.《郁证发微六十论》[M]. 北京:人民卫生出版社,2021: 12.
文燕,陈珑,王挺,等. 小柴胡汤加减治疗抑郁症临床疗效的Meta分析[J]. 上海中医药杂志,2022, 56(1): 34-38.
刘璇,贾新华,张心月,等. 甘草干姜汤治疗肺阳虚类病证临床研究进展[J]. 山东中医药大学学报,2022, 46(3): 411-415.
0
浏览量
1089
下载量
0
CSCD
3
CNKI被引量
关联资源
相关文章
相关作者
相关机构